A critical pathway to treat proximal lower-extremity deep vein thrombosis

American Journal of Medicine

Volumn 100, Issue 3, 1996, Pages 283-289

  Pearson, Steven D ^a,b   Lee, Thomas H ^a,b   McCabe Hassan, Sheila ^a   Dorsey, Joseph L ^a   Goldhaber, Samuel Z ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CONSERVATIVE TREATMENT; DEEP VEIN THROMBOSIS; HEALTH CARE QUALITY; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; LEG THROMBOSIS; LENGTH OF STAY; PATIENT CARE; PATIENT EDUCATION; PHLEBOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0029880104     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)89486-7     Document Type: Article

References (33)

1. Hillner BE, Philbrick JT, Becker DM. Optimal management of suspected lower-extremity deep vein thrombosis. Arch Intern Med. 1992;152:165-175.
2. Wheeler AP, Jacquiss RDB, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med. 1988;148:1321-1325.
3. Fennerty AG, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. BMJ. 1985;290:27-28.
4. Leape LL. Practice guidelines and standards: an overview. QRB. 1990;16:42-49.
5. Zander K. Care maps: the core of cost/quality care. The New Definition. 1991;6:1-3.
6. Pearson SD, Polak JL, Cartwright S, et al. A critical pathway to evaluate suspected deep vein thrombosis. Arch Intern Med. 1995;155:1773-1778.
7. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thromboembolism. Arch Intern Med. 1992;152:1589-1595.
8. Cruickshank MK, Levine MN, Hirsh J. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med. 1991;151:333-337.
9. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med. 1993;119:874-881.
10. Elliott CG, Hiltunen SJ, Suchyta M, et al. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med. 1994;154:999-1004.
11. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 1992;102(suppl):408S-425S.
12. Goldberg RJ, Seneff M, Gore JM, et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med. 1987;147:251-253.
13. Heijboer H, Brandjes DP, Buller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. NEJM. 1990;323:1512-1516.
14. Bolan CD, Alving BM. Recurrent venous thrombosis and hypercoagulable states. Am Fam Physician. 1991;44:1741-1751.
15. Freed JA. Hypercoagulability. Should every patient with venous thrombosis be tested? Postgrad Med. 1991;90:157-160, 165-166, 168.
16. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
17. Tuddenham EGD. Thrombophilia: the new factor is old factor V. Lancet. 1994;343:1515-1516.
18. Gallus A, Jackman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986;2:1293-1296.
19. Mohiuddin SM, Hilleman DE, Destache CJ, et al. Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism. Am Heart J 1992;123:729-732.
20. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. NEJM. 1990;322:1260-1264.
21. Ansell J. Oral anticoagulant therapy-50 years later. Arch Intern Med. 1993;153:586-596.
22. Hyers TM, Hull RD, Weg JC. Antithrombotic therapy for venous thromboembolic disease. Chest. 1992;102:408S-425S.
23. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1992;102(suppl):312S-326S.
24. Brandjes DPM, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. NEJM. 1992;327:1485-1489.
25. Zauber NP, Stark MS. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med. 1986;104: 659-660.
26. Enzenauer RJ, Campbell J. Progressive warfarin anticoagulation in protein C deficiency: a therapeutic strategy. Am J Med. 1990;88:697-698.
27. Hirsh J. Oral anticoagulant drugs. NEJM. 1991;324:1865-1875.
28. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. NEJM. 1982;307:1676-1681.
29. Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. NEJM. 1975;292:1045-1050.
30. Filshie I, Scott GBD. The organization of experimental venous thrombi. J Pathol Bacteriol. 1958;76:71-76.
31. Rooke TW, Osmundson PJ. Heparin and the in-hospital management of deep venous thrombosis: cost considerations. Mayo Clin Proc. 1986;61: 198-204.
32. Gottlieb LK, Sokol HN, Murrey KO, et al. Algorithm-based clinical quality improvement. Clinical guidelines in continuous quality improvement. HMO Practice. 1992;6:5-12.
33. Handley MR, Stuart ME. An evidence-based approach to evaluating and improving clinical practice: guideline development HMO Practice. 1994;8:10-19.